The stem cell therapy developer, exploiting research from Digital Photonics and Nanoscience Laboratory, has set up a US subsidiary.

TreeFrog Therapeutics, a France-based stem cell therapy developer advancing research from Digital Photonics and Nanoscience Laboratory (LP2N), completed a $75m series B round yesterday led by Bpifrance’s Large Venture fund. Investment firm Leonard Green & Partners and XAnge, the venture capital arm of private equity group Siparex, also took part in the round, as did…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.